Zobrazeno 1 - 10
of 88
pro vyhledávání: '"G. Varkas"'
Autor:
Lieve Gyselbrecht, Liesbet Van Praet, G. Varkas, I Peene, H. Cypers, Dirk Elewaut, Kristof Thevissen, Mieke Devinck, Rik Joos, Ann-Sophie De Craemer, Philippe Carron, Félicie Costantino, Jan T. M. Lenaerts, Liselotte Deroo, Maria Antonietta D'Agostino, Thomas Renson, Filip Van den Bosch
Publikováno v:
Rheumatology. 61:3279-3288
Objectives To delineate the impact of peripheral musculoskeletal manifestations on stratification of disease phenotype and outcome in new-onset spondyloarthritis (SpA), using a prospective observational nationwide inception cohort, the BelGian Inflam
Autor:
Ann-Sophie De Craemer, Anaïs Depicker, Philippe Carron, Griet Vandenberghe, G. Varkas, Nele Herregods, Isabelle Dehaene, Filip Van den Bosch, Liselotte Deroo, Thomas Renson, Kristien Roelens, Dirk Elewaut, Lennart Jans, Manouk de Hooge
Publikováno v:
Annals of the Rheumatic Diseases. 79:929-934
ObjectivesBone marrow oedema (BMO) on MRI of sacroiliac joints (SIJs) represents a hallmark of axial spondyloarthritis (SpA), yet such lesions may also occur under augmented mechanical stress in healthy subjects. We therefore sought to delineate the
Autor:
Filip Van den Bosch, Martine De Vos, G. Varkas, Rik Lories, Clio Ribbens, Edouard Louis, Dirk Elewaut, Severine Vermeire
Publikováno v:
Alimentary Pharmacology & Therapeutics. 50:1204-1213
BACKGROUND: Spondyloarthritis is the most frequent extra-intestinal manifestation of IBD. AIM: To present simple strategies to identify and differentiate inflammatory joint pain in IBD patients. METHODS: A panel of Belgian gastroenterologists and rhe
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ainara Elorza, C De Galan, M. De Vos, L Vandermeulen, A Jauregui Amezaga, R Ferreiro-Iglesias, F Mesonero Gismero, L Peries Reverter, Jeroen Geldof, T Lobaton, Harald Peeters, Tom Holvoet, Y Zabana, Paola Torres, M Truyens, G. Varkas
Publikováno v:
Journal of Crohn's and Colitis. 15:S302-S302
Background Extra-intestinal manifestations (EIM) are frequently reported in inflammatory bowel diseases (IBD). Although the efficacy of TNF inhibitors is well documented, data regarding the effect of vedolizumab (VDZ) and ustekinumab (UST) are limite
Autor:
Joke Van Vlaenderen, Joke Dehoorne, Lennart Jans, Koenraad Verstraete, G. Varkas, Dirk Elewaut, Rik Joos, Filip Van den Bosch, Nele Herregods, Xenofon Baraliakos, Jacob L. Jaremko
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 15, Iss 1, Pp 1-10 (2017)
Pediatric Rheumatology Online Journal
PEDIATRIC RHEUMATOLOGY
Pediatric Rheumatology Online Journal
PEDIATRIC RHEUMATOLOGY
Background The Assessment of Spondyloarthritis International Society (ASAS) definition for a ‘positive’ Magnetic Resonance Imaging (MRI) for sacroiliitis is well studied and validated in adults, but studies about the value of this definition in c
Publikováno v:
Annals of the Rheumatic Diseases. 76:1389-1395
ObjectiveTo evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA).MethodsClinical REmission in peripheral SPondyloArthritis is a monocentric study of golimum
Autor:
M Truyens, Jeroen Geldof, G Dewitte, Elien Glorieus, Dirk Elewaut, G Varkas, T. Lobaton Ortega
Publikováno v:
Journal of Crohn's and Colitis. 14:S546-S547
Background Vedolizumab (VDZ), a gut-specific anti-integrin, is approved as a treatment for moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). Extra-intestinal manifestations (EIMs) are frequently associated with inflammatory bowel
Autor:
Philippe Carron, Pieter Hindryckx, H. Cypers, L. Van Praet, I. Vanneuville, J. De Kock, M. De Vos, G. De Brabanter, Kristof Thevissen, G. Varkas, Frank Czul-Gurdian, J. Arts, Barbara Claerhout, F. Van den Bosch, Maria T. Abreu, Dirk Elewaut, P. Schoenaers
Publikováno v:
Annals of the Rheumatic Diseases. 76:878-881
BackgroundIn inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect